Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...
CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...
Should you be buying the dip? Let's find out. CSL shares crashed 39% during 2025 to $172.65 as management slashed revenue and profit growth guidance, signalling that the biotherapeutics giant's next ...
uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Michal studies Automotive Journalism at Coventry University in the UK, and has been writing for CarBuzz since March 2025. He was nominated for student culture piece of the year recently and has been ...
About DuPont de Nemours Inc. DuPont de Nemours, Inc. is a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results